Clinical Trial Update: Phase 1 Study of ACE-232 to Treat Patients With Metastatic Castration-Resistant Prostate Cancer [Phase 1]

View source ↗

Summary

A Phase 1 study of ACE-232 for metastatic castration-resistant prostate cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• ACE-232

Snippet

Sponsor: Acerand Therapeutics (Hong Kong) Limited | Conditions: Prostate Cancer (Adenocarcinoma), mCRPC (Metastatic Castration-resistant Prostate Cancer) | Phase 1 | Status: RECRUITING